Pharma companies and their allies seek to exempt orphan drugs from state pricing limits; Prometheus team launches new startup with $400 million to tackle immune-driven disorders

Taking stock of the drug industry, from the lab to the medicine chest

March 21, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Pharma companies and their allies seek to exempt orphan drugs from state pricing limits Opponents argue exemptions would unnecessarily extend to numerous big-selling treatments for common conditions that happen to have an orphan designation. By Ed Silverman STAT+ | Prometheus team launches new startup with $400 million to tackle immune-driven disorders The company, based in San Diego, is developing drugs for immune-driven conditions affecting the gastrointestinal tract, lung, and skin. By Allison DeAngelis STAT+ | U.K. health officials and researchers try to carve a path for more individualized genetic treatments No individualized treatment has been designed and given to a patient in the U.K. yet, but advocates say they see an opportunity in the country. By Andrew Joseph STAT STAT+ | Regeneron's plot to 'cure' allergies At STAT Breakthrough Summit, Regeneron's George Yancopoulos discusses new allergy treatments, better weight loss drugs, and his high school science project. By Damian Garde STAT+ | Feng Zhang suggests Editas didn't move quickly enough to find product targets After being seen as a pacesetter in the field of CRISPR medicines, Editas is seen as lagging behind its peers. By Andrew Joseph

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser